The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients.

IF 1.5 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Journal of Research in Medical Sciences Pub Date : 2024-02-23 eCollection Date: 2023-01-01 DOI:10.4103/jrms.jrms_271_23

Shiva Seirafian, Awat Feizi, Shahrzad Shahidi, Shirin Sadat Badri, Mohammad Hossein Rouhani, Pejman Pourazari Najafabadi, Elham Kabiri Naeini

{"title":"The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients.","authors":"Shiva Seirafian, Awat Feizi, Shahrzad Shahidi, Shirin Sadat Badri, Mohammad Hossein Rouhani, Pejman Pourazari Najafabadi, Elham Kabiri Naeini","doi":"10.4103/jrms.jrms_271_23","DOIUrl":null,"url":null,"abstract":"Background: In hemodialysis (HD) patients, low serum zinc level could cause hyporesponsivity to erythropoiesis-stimulating agents and lead to anemia. This study investigated the effects of oral zinc supplements on the required dose of erythropoietin in patients undergoing HD.Materials and methods: In a double-blinded randomized trial, 76 HD patients were assigned to 2 groups of 38. One group (intervention) was treated with oral zinc supplements of 210 mg, daily for 6 months, and the other group (control) used placebo capsules for 6 months. The serum zinc level, hemoglobin level, and required dose of erythropoietin, albumin, ferritin, ferrous, and total iron-binding capacity were evaluated 3 and 6 months after intervention.Results: Repeated measures ANOVA did not show a significant increase in Hb level after 6 months of intervention (P = 0.28). However, the required dose of erythropoietin was decreased, but the changes were not statistically significant (P > 0.05). The changes in the other variables were not statistically significant.Conclusion: Oral zinc supplementation in HD patients could not increase hemoglobin level irrespective of their serum zinc level.","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"85"},"PeriodicalIF":1.5000,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953733/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jrms.jrms_271_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In hemodialysis (HD) patients, low serum zinc level could cause hyporesponsivity to erythropoiesis-stimulating agents and lead to anemia. This study investigated the effects of oral zinc supplements on the required dose of erythropoietin in patients undergoing HD.

Materials and methods: In a double-blinded randomized trial, 76 HD patients were assigned to 2 groups of 38. One group (intervention) was treated with oral zinc supplements of 210 mg, daily for 6 months, and the other group (control) used placebo capsules for 6 months. The serum zinc level, hemoglobin level, and required dose of erythropoietin, albumin, ferritin, ferrous, and total iron-binding capacity were evaluated 3 and 6 months after intervention.

Results: Repeated measures ANOVA did not show a significant increase in Hb level after 6 months of intervention (P = 0.28). However, the required dose of erythropoietin was decreased, but the changes were not statistically significant (P > 0.05). The changes in the other variables were not statistically significant.

Conclusion: Oral zinc supplementation in HD patients could not increase hemoglobin level irrespective of their serum zinc level.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

口服锌对血液透析患者血红蛋白和促红细胞生成素剂量的影响。

背景：在血液透析（HD）患者中，血清锌水平低会导致对促红细胞生成药物的反应迟钝，从而导致贫血。本研究调查了口服锌补充剂对血液透析患者所需红细胞生成素剂量的影响：在一项双盲随机试验中，76 名血液透析患者被分为两组，每组 38 人。一组（干预组）每天口服 210 毫克锌补充剂，持续 6 个月；另一组（对照组）服用安慰剂胶囊，持续 6 个月。干预3个月和6个月后，对血清锌水平、血红蛋白水平、促红细胞生成素所需剂量、白蛋白、铁蛋白、亚铁和总铁结合能力进行评估：结果：重复测量方差分析显示，干预 6 个月后，血红蛋白水平没有显著提高（P = 0.28）。不过，所需的促红细胞生成素剂量有所减少，但变化无统计学意义（P > 0.05）。其他变量的变化无统计学意义：结论：无论血清锌水平如何，口服锌补充剂都无法提高 HD 患者的血红蛋白水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Research in Medical Sciences MEDICINE, GENERAL & INTERNAL-

CiteScore

2.60

自引率

6.20%

发文量

审稿时长

3-6 weeks

期刊介绍： Journal of Research in Medical Sciences, a publication of Isfahan University of Medical Sciences, is a peer-reviewed online continuous journal with print on demand compilation of issues published. The journal’s full text is available online at http://www.jmsjournal.net. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.